Cocrystal Pharma Stock (NASDAQ:COCP)


RevenueOwnershipFinancialsChart

Previous Close

$2.25

52W Range

$1.33 - $3.10

50D Avg

$1.96

200D Avg

$1.91

Market Cap

$27.37M

Avg Vol (3M)

$21.94K

Beta

1.45

Div Yield

-

COCP Company Profile


Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Feb 22, 2012

Website

COCP Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 20Jun 20
Collaboration Revenue$489.00K$554.00K

Fiscal year ends in Dec 23 | Currency in USD

COCP Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-240.00K$-38.83M$-14.22M
Net Income-$-38.84M$-14.19M
EBITDA$-240.00K$-17.75M$-14.03M
Basic EPS-$-4.77$-1.93
Diluted EPS-$-4.77$-1.93

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
REVBRevelation Biosciences, Inc.
BDRXBiodexa Pharmaceuticals Plc
PULMPulmatrix, Inc.
IKNAIkena Oncology, Inc.
CYCCCyclacel Pharmaceuticals, Inc.
BPTHBio-Path Holdings, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
RNXTRenovoRx, Inc.
TPSTTempest Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
MBRXMoleculin Biotech, Inc.